Written and maintained by CASRAI Editorial Board
Last updated
Short answer: The Pharmaceuticals and Medical Devices Agency (PMDA) is a Japanese incorporated administrative agency, established on April 1, 2004, whose stated obligation is to protect public health by assuring the safety, efficacy and quality of pharmaceuticals and medical devices. It does three things: reviews, post-marketing safety measures and relief services for adverse health effects.
Definition and scope
PMDA describes its legal form as an “incorporated administrative agency with non-civil service status” and says it works together with the Ministry of Health, Labour and Welfare (MHLW). PMDA is therefore an agency in its own right and not the ministry itself. Its outline page lists three areas of service:
- Reviews of drugs, medical devices, and cellular and tissue-based products.
- Post-marketing safety measures, meaning the collection, analysis and provision of safety information after products are on the market.
- Relief services for adverse health effects.
For labs and clinics that handle Japanese-market products or run studies that report to Japan, the first two areas are the ones that show up in day-to-day paperwork.
How PMDA’s review services work in practice
PMDA’s review-services outline says that during review, PMDA evaluates the quality, efficacy and safety of drugs, medical devices and cellular and tissue-based products against current scientific and technological standards. Around that core review, the same page names three kinds of related activity.
Consultations
Consultations are described as advice in relation to regulatory submissions. They are a service sponsors and manufacturers use before and during a submission, and they are separate from the review decision itself.
Compliance assessments of submitted data
GLP, GCP and GPSP inspections are carried out “to ensure the submitted data are in compliance with the ethical and scientific standards.” For clinical work, the GCP reference point is covered in our guide to Good Clinical Practice.
Inspections of manufacturing quality
GMP, QMS and GCTP inspections are carried out “to ensure quality management of the manufacturing facility for the product submitted for approval.” For devices, the quality-management-system context is explained in ISO 13485 certification.
PMDA services at a glance: what is checked and what is advised
This comparison uses PMDA’s own wording. It separates activities that look at the data, the manufacturing site, or the sponsor’s plan.
| PMDA activity | Subject of the activity | Stated purpose |
|---|---|---|
| Consultations | Regulatory submission plans | Providing advice in relation to regulatory submission |
| GLP / GCP / GPSP inspections | Data submitted with an application | Ensure the data comply with ethical and scientific standards |
| GMP / QMS / GCTP inspections | The manufacturing facility | Ensure quality management of the facility for the product submitted for approval |
| Post-marketing safety measures | Products already on the market | Post-marketing safety information for healthcare professionals, such as safety communications and package insert revisions |
Related concepts and how they connect
Several CASRAI pages cover neighbouring topics that mention Japan or PMDA:
- PMDA clinical trial notification (CTN), the term for the notification step used before a clinical trial in Japan.
- ICH (International Council for Harmonisation), the body behind many of the shared technical guidelines regulators use.
- eCTD structure for clinical submissions, on how submission dossiers are organised.
- MDSAP, an audit programme relevant to device manufacturers selling in several jurisdictions.
Where it matters for labs, clinics and supply decisions
PMDA’s post-marketing safety section is the part most useful to people who handle products rather than file applications. On the English site, the “For Healthcare Professionals” area lists safety information items: The Yellow Letter / Blue Letter, Revisions of Drug Package Inserts, “PMDA Alert for Proper Use of Drugs” and “PMDA Medical Safety Information”.
A practical checklist for staff who track products used in Japan:
- Know which PMDA area a document comes from (review, safety, or relief), because each answers a different question.
- Look in the post-marketing safety section for package insert revisions and safety communications that affect products already in use.
- Use the “Information for approved products in Japan” listing for drugs, medical devices, regenerative medical products and companion diagnostics.
- Note that PMDA’s site states that machine translation may be inaccurate and that PDF, Excel, Word and PowerPoint files are not translated.
For the general idea of what counts as a medical device in the first place, see What is a medical device?. For keeping track of rule changes across regulators, see building a regulatory intelligence function.
Common misunderstandings
PMDA is not the ministry
PMDA describes itself as working together with the Ministry of Health, Labour and Welfare. PMDA is an incorporated administrative agency with its own services, and this page does not address which body grants approvals.
PMDA does more than review
A common shorthand treats PMDA as “Japan’s approval agency”. Its own outline lists post-marketing safety measures and relief services alongside reviews.
An inspection is not the same as a consultation
Consultations provide advice on a submission. GLP, GCP, GPSP, GMP, QMS and GCTP inspections check data and manufacturing quality.
FAQ
What does PMDA stand for?
Pharmaceuticals and Medical Devices Agency.
When was PMDA established?
April 1, 2004, according to PMDA’s outline page.
What does PMDA review?
Drugs, medical devices, and cellular and tissue-based products, evaluating their quality, efficacy and safety.
Where does PMDA publish safety information?
In the Post-marketing Safety Measures area of its English site, including The Yellow Letter / Blue Letter, revisions of drug package inserts, “PMDA Alert for Proper Use of Drugs” and “PMDA Medical Safety Information”.
Sources
- PMDA, Outline of PMDA: https://www.pmda.go.jp/english/about-pmda/outline/0005.html (checked 2026-10-29)
- PMDA, Review Services outline: https://www.pmda.go.jp/english/review-services/outline/0001.html (checked 2026-10-29)
- PMDA, Post-marketing Safety index: https://www.pmda.go.jp/english/safety/index.html (checked 2026-10-29)
